Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium (Q27009385)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium	scientific article

Statements

scholarly article

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2 references

Europe PubMed Central

8 September 2020

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2 references

6 August 2019

8 September 2020

pharmaceutical preparation

1 reference

6 August 2019

investigational drugs

1 reference

8 September 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sébastien Lacroix-Desmazes

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

25

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Gilles Paintaud

29

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

B Rup

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Pallardy

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Sikkema

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

T Albert

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Allez

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Carini

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

P Creeke

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Davidson

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Finco

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A Fogdell-Hahn

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

E Havrdova

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A Hincelin-Mery

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M C Holland

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

P E H Jensen

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

E C Jury

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H Kirby

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Kramer

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Legrand

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

E Maggi

22

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

B Maillère

23

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

X Mariette

24

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

V Mikol

26

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

D Mulleman

27

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Oldenburg

28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C R Pedersen

30

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Ruperto

31

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Seitz

32

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

S Spindeldreher

33

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

F Deisenhammer

34

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

ABIRISK Consortium

35

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

1 reference

publication date

2 July 2015

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 September 2015

1 reference

8 September 2020

Clinical and Experimental Immunology

4 references

6 August 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

8 September 2020

181

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

3

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

385-400

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

20 December 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

21 March 2017

Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Protein-based matrix interferences in ligand-binding assays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Therapeutic proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Impact of product-related factors on immunogenicity of biotherapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

The safety and side effects of monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Epoetin-associated pure red cell aplasia: past, present, and future considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Protein therapeutics: a summary and pharmacological classification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

The epidemiology of inhibitors in haemophilia A: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Thrombocytopenia caused by the development of antibodies to thrombopoietin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

The effector functions of immunoglobulins: implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 September 2017

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

31 May 2018

Factor IX inhibitors and anaphylaxis in hemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Haemophilia care in Europe - a survey of 35 countries

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay.

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

A survey of applications of biological products for drug interference of immunogenicity assays

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 November 2018

Taking immunogenicity assessment of therapeutic proteins to the next level.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557374

28 November 2018

Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Immunoglobulin Subclasses in Patients with Neutralizing and Nonneutralizing Antibodies Against IFN-β1b

1 reference

https://api.crossref.org/works/10.1111%2FCEI.12652

21 January 2018

Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interchangeability, immunogenicity and biosimilars

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practical application of acid dissociation in monitoring patients treated with adalimumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification and inhibition of drug target interference in immunogenicity assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab dosage suspension: are we helping or hurting?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25959571

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/CEI.12652

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25959571%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27009385&oldid=1857219458"